| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 07/31/2003 | WO2003061689A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | WO2003061687A1 High-concentration preparation of soluble thrombomodulin |
| 07/31/2003 | WO2003061677A1 The healthy patch with the functions of accelerating blood circulation and expelling toxin |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061634A1 Sustained release pharmaceutical composition |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061593A2 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | WO2003061379A2 Methods for inactivation of pathogens in biological materials |
| 07/31/2003 | WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002058716A3 Treatment of inflammatory bowel disease using growth factors |
| 07/31/2003 | WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002024909A3 Receptor nucleic acids and polypeptides |
| 07/31/2003 | WO2002004010A3 Inhibition of tumor growth by a nematode anticoagulant protein |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144350 Modulating fatty acid or triglyceride accumulation by cells; treating obesity and metabolic disorders |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144334 Cyclopentabenzofuran derivatives and their use |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144305 Novel compounds |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144287 Heterocyclic amides such as N-(4-(2-(((methyl)amino)methyl)-1H-imidazol-1-yl)-2-fluorophenyl)-1-(3-amino-1,2-benzisoxazol-5-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, used as anticoagulants; prophylaxis of cardiovascular disorders |
| 07/31/2003 | US20030144283 Amide substituted imidazoquinolines |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144211 Inhibit leukocyte adhesion to endothelium or to platelets |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144187 Comprising an osteoprotegerin polypeptide and an immunoglobulin FC region; treatment of bone disorders |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143289 For therapy of cerebral vascular disease, including stroke, intracranial hemorrhage, intracranial infarction, and vascular dementia |
| 07/31/2003 | US20030143285 For therapy andprophylaxis of disease-like conditions caused by extreme body fluid discharge |
| 07/31/2003 | US20030143284 Food product comprising a high level of natural anti-secretory protein |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143226 For therapy of arteriosclerosis, thrombocytopenia, kidneyd iseases, various types of inflammation such as myocardial ischemic reperfusion injury, inflammatory reactions after percutaneous transluminal coronary recanalization (PTCR)) |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143215 Carbonyl stress-ameliorating agents |
| 07/31/2003 | US20030143157 Method of treating tumors |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2511223A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473748A1 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | CA2473740A1 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | CA2434256A1 Methods for inactivation of pathogens in biological materials |
| 07/30/2003 | EP1331268A1 Novel proteins, genes encoding them and method of using the same |
| 07/30/2003 | EP1331228A1 Method of screening antiplatelet |
| 07/30/2003 | EP1331221A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 07/30/2003 | EP1330463A2 Beta-substituted beta-aminoethyl phosphonates |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330428A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 07/30/2003 | EP1330425A2 C-nitroso compounds and use thereof |
| 07/30/2003 | EP1330260A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 07/30/2003 | EP1330166A1 Food grade transglutaminase inhibitor and uses thereof |
| 07/30/2003 | EP1165121B1 SUPAR STIMULATING ACTIVITY OF tcuPA-MEDIATED FIBRINOLYSIS AND DIFFERENT USES THEREOF |
| 07/30/2003 | EP0964684B1 Crystalline pharmaceutical product |
| 07/30/2003 | EP0859628B1 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
| 07/30/2003 | EP0702696B1 Trifunctional antithrombin and antiplatelet peptides |
| 07/30/2003 | CN1433469A Therapeutically useful synthetic oligonucleotides |
| 07/30/2003 | CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 07/30/2003 | CN1433416A N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433415A N-[5-[[[5-alkyl-2-oxazlyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433396A Pharmaceutical compounds |
| 07/30/2003 | CN1433320A Carbonyl stress-ameliorating agents |
| 07/30/2003 | CN1432406A Application of snake venom protein hydrolase in preparing medicine |
| 07/30/2003 | CN1116304C Organic compound |
| 07/30/2003 | CN1116042C Coposition containing chlopidogrel and antithrombotic agent active component |
| 07/30/2003 | CN1116037C Use of flupirtin for prevention and treatment of disease which are associated with damage to haemopoietic cell system |
| 07/29/2003 | US6600059 Protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents. Even more particularly, the present invention provides compositions and methods for treating or prophylactically inhibiting |
| 07/29/2003 | US6600038 Carbamoyl tetrahydropyridine derivatives |
| 07/29/2003 | US6599932 Highly selective in killing tumor cells but not normal cells |
| 07/29/2003 | US6599926 Anticoagulant agents for treatment and prevention of thromboembolic disorders |
| 07/29/2003 | US6599925 Cardiovascular disorders; anticancer agents |
| 07/29/2003 | US6599918 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans |
| 07/29/2003 | US6599910 Substituted triazole compounds |
| 07/29/2003 | US6599894 Competitive inhibitors of trypsin-like proteases, such as thrombin, and in treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants |
| 07/29/2003 | US6599890 Inhibitors of matrix metalloproteinases or the production of tumor necrosis factor |